Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Primary Sponsor

ANZUP

Collaborating Groups

NHMRC CTC, TROG Cancer Research

Participating Centres

Current Accrual

Trial Chairperson

Prof Christopher Sweeney and Assoc/Prof Tamim Niazi

Trial Contact

dasl.study@sydney.edu.au

Related Post

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

Skip to toolbar